Neuraltus Pharmaceuticals

Latest Headlines

Latest Headlines

Neuraltus Pharma eyes PhIII after missing endpoints in trial for ALS drug

Despite falling short of goals in a Phase II trial, Neuraltus Pharmaceuticals saw enough evidence of efficacy in Lou Gehrig's disease patients on its experimental drug to push forward plans for a late-state study. Its decision to start the Phase III program next year underscores the critical need for new therapies against the muscle-disabling disorder.

A DIY clinical study? Desperate patients try a therapeutic 'home brew'

In this case the object of their desperation is NP001, an experimental drug now in a Phase II study.

Biotech startup touts biomarker effect in PhI ALS study

A small Palo Alto, CA-based biotech has garnered some fresh attention for itself after touting the results of a small Phase I study designed to test its lead drug by measuring its impact on a key...

Neuraltus Pharma raises $17M in first round

Neuraltus Pharmaceuticals, a biotech developing small molecule drugs for neurodegenerative diseases, has wrapped a $17 million Series A round. Co-investing in the Series A funding are Latterell